Home
Products
Chonglou Saponin VII
| Product Name | Chonglou Saponin VII |
| Price: | $117 / 20mg |
| Catalog No.: | CN02500 |
| CAS No.: | 68124-04-9 |
| Molecular Formula: | C51H82O21 |
| Molecular Weight: | 1031.2 g/mol |
| Purity: | >=98% |
| Type of Compound: | Steroids |
| Physical Desc.: | Powder |
| Source: | The roots of Paris polyphylla |
| Solvent: | DMSO, Pyridine, Methanol, Ethanol, etc. |
| SMILES: | OCC1OC(OC2CCC3(C(=CCC4C3CCC3(C4CC4C3(O)C(C)C3(O4)CCC(CO3)C)C)C2)C)C(C(C1OC1OC(C)C(C(C1O)O)OC1OC(C)C(C(C1O)O)O)O)OC1OC(C)C(C(C1O)O)O |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii Maxim. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia[1]. |
| Target | Akt p38 Bcl-2 Caspase-9 Caspase-3 PARP-1 |
| In Vitro | Paris saponin VII (Chonglou Saponin VII) inhibits the growth of adriamycin-resistant human leukemia cells (K562/ADR) in a dose-dependent manner. Paris saponin VII significantly suppresses cell proliferation by cell cycle arrest in the G0/G1 phase[1]. |
| In Vivo | Paris saponin VII (Chonglou Saponin VII) (intravenous administration) significantly enhances anticancer efficacy of adriamycin to MCF-7/ADR xenograft model in nude mice[2]. |
| Density | 1.5±0.1 g/cm3 |
| Exact Mass | 1030.534912 |
| PSA | 314.83000 |
| LogP | 4.91 |
| Storage condition | -20℃ |